Development of population-level colon cancer pathway concordance measures and association with survival.

colonic neoplasms guideline adherence medical informatics computing pathway concordance survival rate

Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
15 06 2022
Historique:
revised: 06 12 2021
received: 24 03 2021
accepted: 04 01 2022
pubmed: 17 2 2022
medline: 20 4 2022
entrez: 16 2 2022
Statut: ppublish

Résumé

Clinical cancer pathways help standardize healthcare delivery to optimize patient outcomes and health system costs. However, population-level measurement of concordance between standardized pathways and actual care received is lacking. Two measures of pathway concordance were developed for a simplified colon cancer pathway map for Stage II-III colon cancer patients in Ontario, Canada: a cumulative count of concordant events (CCCE) and the Levenshtein algorithm. Associations of concordance with patient survival were estimated using Cox proportional hazards models adjusted for patient characteristics and time-dependent cancer-related activities. Models were compared and the impact of including concordance scores was quantified using the likelihood ratio chi-squared test. The ability of the measures to discriminate between survivors and decedents was compared using the C-index. Normalized concordance scores were significantly associated with patient survival in models for cancer stage-a 10% increase in concordance for Stage II patients resulted in a CCCE score adjusted hazard ratio (aHR) of death of 0.93, 95% CI 0.88-0.98 and a Levenshtein score aHR of 0.64, 95% CI 0.60-0.67. A similar relationship was found for Stage III patients-a 10% increase in concordance resulted in a CCCE aHR of 0.85, 95% CI 0.81-0.88 and a Levenshtein aHR of 0.78, 95% CI, 0.74-0.81. Pathway concordance can be used as a tool for health systems to monitor deviations from established clinical pathways. The Levenshtein score better characterized differences between actual care and clinical pathways in a population, was more strongly associated with survival and demonstrated better patient discrimination.

Identifiants

pubmed: 35170750
doi: 10.1002/ijc.33964
pmc: PMC9311776
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2046-2057

Informations de copyright

© 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Références

Ann Hematol. 2008 Feb;87(2):139-45
pubmed: 17938926
Int J Cancer. 2022 Jun 15;150(12):2046-2057
pubmed: 35170750
J Biomed Inform. 2013 Feb;46(1):111-27
pubmed: 23085455
Clin Med (Lond). 2004 Mar-Apr;4(2):132-5
pubmed: 15139730
Ann Intern Med. 2015 Jan 6;162(1):W1-73
pubmed: 25560730
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Clin Colorectal Cancer. 2016 Jun;15(2):179-85
pubmed: 26520019
AMIA Annu Symp Proc. 2014 Nov 14;2014:1208-17
pubmed: 25954432
J Thorac Cardiovasc Surg. 2007 Apr;133(4):865-75
pubmed: 17382616
Clin Oncol (R Coll Radiol). 2017 Jul;29(7):459-465
pubmed: 28341242
Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006632
pubmed: 20238347
BMC Med. 2016 Feb 23;14:35
pubmed: 26904977
Appl Clin Inform. 2013 Mar 20;4(1):126-43
pubmed: 23650493
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Health Rep. 2012 Sep;23(3):43-51
pubmed: 23061264
Curr Oncol. 2020 Feb;27(1):e27-e33
pubmed: 32218665
Stud Health Technol Inform. 2012;180:995-9
pubmed: 22874343
J Med Screen. 2018 Sep;25(3):141-148
pubmed: 28862521
J Clin Oncol. 2013 Apr 10;31(11):1471-7
pubmed: 23478057
Can J Surg. 2009 Apr;52(2):92-7
pubmed: 19399202
BMC Med. 2010 May 27;8:31
pubmed: 20507550
Aust Health Rev. 2007 Nov;31(4):565-70
pubmed: 17973615
J Oncol Pract. 2016 Mar;12(3):261-6
pubmed: 26759491

Auteurs

Luciano Ieraci (L)

Data and Decision Sciences, Ontario Health (Cancer Care Ontario), Toronto, Ontario, Canada.
Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.

Maria Eberg (M)

IQVIA, 16720 Rte. Transcanadienne, Kirkland, Quebec, Canada.

Katharina Forster (K)

Disease Pathway Management, Ontario Health (Cancer Care Ontario), Toronto, Ontario, Canada.

Paula M Murray (PM)

Children's Hospital Los Angeles, Los Angeles, California, USA.

Emmett Borg (E)

Hoffmann-La Roche, Mississauga, Ontario, Canada.

Steven Habbous (S)

Quality Measurement and Evaluation, Ontario Health (Cancer Care Ontario), Toronto, Ontario, Canada.

Ali Vahit Esensoy (AV)

Klick Labs, Klick Health, Toronto, Ontario, Canada.

Erin Kennedy (E)

Disease Pathway Management, Ontario Health (Cancer Care Ontario), Toronto, Ontario, Canada.
Quality Measurement and Evaluation, Ontario Health (Cancer Care Ontario), Toronto, Ontario, Canada.

Claire M B Holloway (CMB)

Disease Pathway Management, Ontario Health (Cancer Care Ontario), Toronto, Ontario, Canada.
Department of Surgery, University of Toronto, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH